Adrian Parton, MBE, of Boundary Capital has backed Capital Cell, Europe’s first dedicated Life Sciences crowdfunding platform.

Capital Cell works with companies whose technology is based on biology or healthcare to secure the investment they need to progress their innovative, potentially life-changing ideas. Capital Cell’s model is to support early stage companies, with seed stage investment up to £1 million sought through the platform.

Founded in Spain in 2014, Capital Cell is already building a track-record in raising investment to progress promising medical inventions and secure a return to investors. This expansion into the UK market sees Capital Cell establish a presence in the leading biotech market in Europe. The Company is backed in its expansion by a number of leading UK life sciences innovators and investors, including: Dr Harren Jhoti, founder and CEO of Astex Pharmaceuticals; the life sciences angel investor David Ford; Adrian Parton, MBE, of Boundary Capital and serial life sciences entrepreneurs Sunil and Prashant Shah of O2h Ventures. Dr Ian Tomlinson – founder of Domantis, sold to GSK and now supporting a number of innovative life sciences companies as Chairman and board member, including Stevenage BioScience Catalyst and Apollo Therapeutics – is also an investor and has been appointed as Chairman of the Board.

Read more here.

Write a comment:

*

Your email address will not be published.

Boundary Capital Partners LLP is authorised and regulated by the Financial Conduct Authority.
Boundary Capital Partners LLP Reg: OC387581 VAT: 204012873
Registered office: 35 Kingsland Road, London, England, E2 8AA

STAY CONNECTED WITH US: